Advertisement

Topics

Companies Related to "Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy" [Most Relevant Company Matches] RSS

14:02 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Efficacy 2043 Subjects Undergoing Coronary Reperfusion Therapy" Companies 1–25 of 2,900+

Extremely Relevant

Ischemix, Inc.

Ischemix is a privately-held, clinical-stage pharmaceutical company developing novel cytoprotective compounds for the prevention and treatment of serious diseases and conditions. The initial focus of the Company is the prevention of acute kidney injury and cardiac injury in patients undergoing cardiac catheterization procedures. Ischemix’ lead product...


Relevant

Solid GT

Solid GT, a subsidiary of Solid Biosciences, is a gene therapy platform focused on developing novel, disease-modifying therapeutics for Duchenne muscular dystrophy. The company’s licensed technology has demonstrated efficacy in various DMD animal models and lead candidates are currently undergoing IND-enabling studies. Founded in 2014, Solid GT is col...

Kepivance™ (palifermin)

Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplant. The safety and efficacy of Kepivance™ have not been established in patients with nonhematologic malignancies.


OncoWell, LLC

OncoWell, LLC, headquartered in New York, NY, provides complementary products and resources to patients undergoing cancer treatment. The company’s first offering, OncoWellCE, is a concentrated enzyme product to support patient wellness while undergoing chemotherapy or radiation therapy. OncoWell, LLC was founded in 2012 by James Nicholls, Peter Jenkin...

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caus...

ProUroCare Medical

Proprietary vision technologies advancing the safety and efficacy of medical diagnostics and therapeutics. ProUroCare Medical Inc. is an early-stage company that is developing innovative sensing and vision technologies to increase the safety and efficacy of medical diagnostics and therapeutic procedures. Currently, we are focused on products and technologies that use minimally invasive techniqu...

Incara Pharmaceuticals Corporation

Incara Pharmaceuticals Corporation conducts discovery and development programs in three areas: (1) inflammatory bowel disease, using an ultra-low molecular weight heparin; (2) liver disorders, using a novel form of hepatic progenitor cell therapy; and (3) novel small molecule antioxidants for disorders such as stroke, asthma and reperfusion injury.

RheoGene Inc

RheoGene is developing the RheoSwitch® Therapeutic System (RTS) for cell and gene therapy. RTS delivers therapeutic gene products in the patient to the right place, at the right time, and at the right dose. Despite advances in the understanding of the genetic and molecular basis of disease, there are no approved gene therapy products on the market today, in part because of the unmet need for effi...

Sunshine Heart, Inc.

Sunshine Heart (ASX:SHC) is a global medical device company committed to novel cardiac and coronary therapy. The company is currently developing the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-...

CathWorks

CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize PCI therapy decisions and elevate coronary angiography from visual assessment to an objective FFR-based decision-making tool for physicians. FFR-guided PCI decision-making is proven to provide significant clinical benefits for patients with...

diaDexus

diaDexus, a privately held biotechnology company, is focused on the discovery, development, and commercialization of novel, patent protected diagnostic products with high clinical value.diaDexus’ lead product, the PLAC® test, is a blood test that measures the concentration of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel risk factor for coronary heart disease and ischemic stroke. T...

PlaqueTec Ltd.

PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory risk. It has been proven to detect inflammatory molecules across the site of coronary artery disease (CAD), and can discriminate between patients with greater and lesser levels of co...

TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...

AlphaCore Pharma

AlphaCore Pharma is an Ann Arbor-based private company focused on the development of ACP-501 as a therapy for acute coronary syndromes, and other high-risk atherosclerosis conditions. ACP-501 is recombinant human lecithin: cholesterol acyltransferase (or rhLCAT), an enzyme required for cholesterol metabolism. Additionally, ACP-501 is being developed to tre...

Quintiles Scotland

Safety PharmacologyQuintiles has safety pharmacology services to identify the potential adverse pharmacological effects of new chemical entities prior to first administration to man. Regulatory Safety Pharmacology packages Haemodynamics/ECG studies Cardiac action potential in vitro QT prolongationIon channels (e.g. HERG) Discovery SupportQuintiles pharmacologists can provide support in defining th...

Foxhollow Technologies

An estimated 12 million people in the U.S. alone have peripheral arterial disease (PAD). At least 40% of them also suffer from coronary artery disease (CAD). FoxHollow recently launched the SilverHawk® Plaque Excision System, a device that removes the plaque that commonly blocks arteries and interrupts blood flow. Unlike stenting and other methods of opening the artery, the SilverHawk removes the...

Augmenix, Inc.

Augmenix, Inc. is a privately held company based in Waltham, Mass., focused on the development and commercialization of implantable biomaterial based solutions for improved radiotherapy safety and/or efficacy. Augmenix's first product, SpaceOAR system is an injectable tissue spacer that will decrease rectal morbidity or enable improved efficacy in prostate radiotherapy. The company was founded in ...

Collateral Therapeutics Incorporated

Collateral's initial non-surgical gene therapy products under investigation are designed to promote and enhance angiogenesis, a natural biological process which results in the growth of additional blood vessels, to increase levels of blood flow to oxygen-deprived tissues. The Company's angiogenic products are administered using methods of gene therapy based on non-surgical adenoviral vector delive...

TrakCel

TrakCel's cell therapy process management solution improves clinical study efficacy and accelerates product scale-up/scale-out by implementing communications technology to integrate the supply chain from end-to-end. The technology provides interactive instructions to professionals within the cell therapy supply chain and gives stakeholders on-demand visibi...

Rcadia Medical Imaging Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The COR Analyzer...

EVOFEM, Inc.

EVOFEM, Inc. (formerly Instead Healthcare) provides women with new and different choices for greater freedom and control of their reproductive and sexual health. The San Diego-based company is dedicated to offering women better options in health care segments where their needs are underserved with products that are thoroughly tested for safety and efficacy...

CLINICAL RESEARCH LABORATORIES, INC

Clinical Research Laboratories, Inc. (CRL) was incorporated in 1992. Today, CRL operates as an independent contract laboratory providing a wide range of clinical safety and efficacy testing to the cosmetic and pharmaceutical industries. Located in central New Jersey, CRL is dedicated to conducting human clinical test procedures to determine the safety and efficacy of cosmetic, personal care, and O...

Rcadia Medical Imaging

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

Rcadia Medical Imaging, Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

TanTec Biosystems, Inc.

TanTec Biosystems is a privately held biotechnology company actively engaged in the development and manufacture of sensitive and dependable biomedical standards for use in virology research and the creation of innovative therapeutics for the treatment of viral complications that arise in individuals with chronic viral disease or undergoing immunosuppressive drug therapy.


More From BioPortfolio on "Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks